🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

38 results for “Celgene Europe Limited” Clear

  1. DEXAMETHASONE, ELRANATAMAB, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  2. Dexamethason 4 mg JENAPHARM®, CC-92480, CC-92480, CC-92480, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, TAZEMETOSTAT, CC-92480, Mekinist 2 mg film-coated tablets, Dexamethason 4 mg GALEN®, Mekinist 0.5 mg film-coated tablets, BET-Inhibitor, CC-92480

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  3. Enasidenib Mesilate, Enasidenib Mesilate, Ivosidenib, Vidaza 25 mg/ml powder for suspension for injection

    Celgene Europe Limited

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  4. Iberdomide, Iberdomide, Iberdomide, Iberdomide, Dexamethasone Tablets BP 2.0mg, Iberdomide, Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , Iberdomide, Iberdomide, DARZALEX 1800 mg solution for injection, Iberdomide, Iberdomide, Iberdomide, Dexamethason-ratiopharm® 4 mg Tabletten

    Celgene Europe Limited

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  5. Lisocabtagene maraleucel

    Celgene Europe Limited

    Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  6. Valemetostat Tosylate, Golcadomide, RITUXIMAB, Valemetostat Tosylate, Golcadomide, RITUXIMAB, Golcadomide

    Celgene Europe Limited

    Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  7. idecabtagene vicleucel

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

    phase 2 small molecule active

    1 trial

  8. A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  9. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial

  10. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)

    Celgene Europe Limited

    Systemic Sclerosis, Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  11. A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  12. A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Celgene Europe Limited

    Acute Myeloid Leukemia and Myelodysplastic Syndromes

    phase 1 other active

    1 trial

  13. Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  14. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources